BSW Wealth Partners Sells 3,464 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

BSW Wealth Partners lowered its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 15.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,626 shares of the company’s stock after selling 3,464 shares during the quarter. BSW Wealth Partners’ holdings in Takeda Pharmaceutical were worth $247,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in TAK. FMR LLC boosted its position in shares of Takeda Pharmaceutical by 10.9% in the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after acquiring an additional 286,052 shares during the period. Stifel Financial Corp lifted its stake in Takeda Pharmaceutical by 103.9% in the 3rd quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after purchasing an additional 224,594 shares in the last quarter. Summit Global Investments boosted its holdings in Takeda Pharmaceutical by 86.0% in the 3rd quarter. Summit Global Investments now owns 415,558 shares of the company’s stock valued at $5,909,000 after purchasing an additional 192,143 shares during the period. Crossmark Global Holdings Inc. grew its position in shares of Takeda Pharmaceutical by 284.9% during the 4th quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock valued at $2,787,000 after purchasing an additional 155,795 shares in the last quarter. Finally, Van ECK Associates Corp increased its holdings in shares of Takeda Pharmaceutical by 6.6% in the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock worth $30,149,000 after purchasing an additional 134,407 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 0.2 %

Shares of TAK stock opened at $13.35 on Thursday. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.08. The business’s fifty day moving average is $13.30 and its 200 day moving average is $13.89. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28. The company has a market capitalization of $42.46 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 0.24 and a beta of 0.51.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.